Questionable Testing Common After Ovarian Cancer Therapy Questionable Testing Common After Ovarian Cancer Therapy

Despite evidence that cancer antigen 125 (CA-125) tests and CT scans for surveillance in ovarian cancer patients are not beneficial after treatment, the practice continues, according to a multicenter study.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: Available online 17 July 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Joseph J. Caumanns, G. Bea A. Wisman, Katrien Berns, Ate G.J. van der Zee, Steven de JongAbstractSWI/SNF chromatin remodeling complexes play an important role in the epigenetic regulation of chromatin structure and gene transcription. Mutual exclusive subunits in the SWI/SNF complex include the DNA targeting members ARID1A and ARID1B as well as the ATPases SMARCA2 and SMARCA4. SWI/SNF complexes are predominantly mutated across cancers. The highest mutation incidence is found in ARID1A, primarily consisti...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
SummaryWe performed an in-vitro study testing the chemosensitivity of peritoneal cancer cell lines (SW620, HCT116, MKN45, 23,132/87, OAW42) to various cytostatic drug regimens. A duplex drug, characterized by reversible linking of the antimetabolites 2 ′-deoxy-5-fluorouridine (5-FdU) and 3’-C-ethynylcytidine (ECyd), was compared to oxaliplatin or to cisplatin plus doxorubicin. The experiments were designed to reflect the conditions of intraperitoneal chemotherapy. CASY® (Cell Analysis System) technology was used to compare the impact of incub ation temperature/duration and drug concentration on the viabilit...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
When it comes to anti-cancer drugs, it’s not only their effectiveness at killing the intended target that we want to know, but also their ability to reach and penetrate the cancer cells. Knowing whether the drug actually enters cancer cells can...
Source: Medgadget - Category: Medical Devices Authors: Tags: Genetics Materials Oncology Source Type: blogs
No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news
TUESDAY, July 17, 2018 -- For women undergoing assisted reproduction, there is no increased risk of corpus uteri or invasive breast cancer, but there is an increased risk of ovarian cancer and in situ breast cancer, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Ovarian Cancer Intervention:   Drug: Apatinib mesylate Sponsor:   First Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Ovarian Cancer Intervention:   Drug: Apatinib mesylate Sponsor:   First Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Therapy | CT Scan | Health | Hematology | Ovarian Cancer | Ovaries | Pathology | PET Scan | Study